Jennison Associates LLC Seagen Inc. Transaction History

Jennison Associates LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$187.64 - $206.25 $1,876 - $2,062	-10 Reduced 0.01%	171,813 $33.1 Million
Q1 2023 Apr 26, 2023	SELL	$127.59 - $203.08 $18.7 Million - $29.8 Million	-146,687 Reduced 46.05%	171,823 $34.8 Million
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $671,356 - $796,052	-5,720 Reduced 1.76%	318,510 $40.9 Million
Q3 2022 Nov 01, 2022	SELL	$135.27 - $180.11 $20.4 Million - $27.1 Million	-150,585 Reduced 31.71%	324,230 $44.4 Million
Q2 2022 Aug 02, 2022	SELL	$108.81 - $179.33 $11.4 Million - $18.8 Million	-104,982 Reduced 18.11%	474,815 $84 Million

Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $4.42 Million - $5.83 Million	-36,955 Reduced 5.99%	579,797 $83.5 Million
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $41.3 Million - $55.2 Million	289,382 Added 88.4%	616,752 $95.4 Million
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $46.6 Million - $55.6 Million	327,370 New	327,370 $55.6 Million
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $9.44 Million - $11.3 Million	-69,873 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$137.51 - $190.8 $33.7 Million - $46.7 Million	-244,948 Reduced 77.81%	69,873 $9.7 Million
Q4 2020 Feb 05, 2021	BUY	$164.63 - $211.93 $51.8 Million - $66.7 Million	314,821 New	314,821 $55.1 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.